Reuven Yeganeh Sells 530,000 Shares of BiomX (NYSEAMERICAN:PHGE) Stock

BiomX Inc. (NYSEAMERICAN:PHGE) Director Reuven Yeganeh sold 530,000 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $5.00, for a total transaction of $2,650,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Reuven Yeganeh also recently made the following trade(s):

• On Monday, March 16th, Reuven Yeganeh sold 450,000 shares of BiomX stock. The stock was sold at an average price of $5.00, for a total value of $2,250,000.00.

BiomX Stock Down 3.6%

Shares of NYSEAMERICAN PHGE traded down $0.19 during midday trading on Wednesday, hitting $5.04. The stock had a trading volume of 52,934 shares, compared to its average volume of 1,183,020. The stock has a 50 day simple moving average of $4.86 and a 200-day simple moving average of $6.36. The company has a market capitalization of $8.01 million, a PE ratio of -0.20 and a beta of 1.68. BiomX Inc. has a 1 year low of $1.50 and a 1 year high of $14.71.

BiomX (NYSEAMERICAN:PHGE) last posted its quarterly earnings data on Thursday, February 19th. The company reported $6.99 EPS for the quarter. As a group, analysts expect that BiomX Inc. will post -2.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered shares of BiomX from a “buy” rating to a “hold” rating in a research report on Monday, March 9th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, BiomX has an average rating of “Hold” and an average target price of $26.00.

Institutional Trading of BiomX

A hedge fund recently bought a new stake in BiomX stock. Alyeska Investment Group L.P. purchased a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned about 5.99% of BiomX at the end of the most recent reporting period. Institutional investors and hedge funds own 40.57% of the company’s stock.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.